NEW YORK – Create Medicines has started clinically testing an in vivo CAR therapy that comprises a cancer-killing medley of T, NK, and myeloid cells.

The European Commission will now consider the committee's positive opinions as it determines whether to grant marketing authorization to the drugs.

The firm said the CHMP would not support the application due to concerns about the control arm used in the Phase III PSMAfore trial.

Regeneron's Otarmeni is the first gene therapy approved for OTOF-related hearing loss, which the firm said it will provide to ...

Company execs still have high hopes for the SERD giredestrant, despite a recent trial failure in first-line metastatic breast ...

Four of nine patients responded to the mesothelin-directed therapy, which uses a multi-chain receptor borrowed from NK cells, ...

Researchers at AACR described the development of a classifier that identified a proportion of tumor samples with HRD that did not have BRCA1/2 mutations.

The firm is hoping to show that ODM-212 has anti-tumor activity and can prevent treatment resistance across multiple cancer indications.

Maze intends to use the net proceeds to advance its lead candidates, kidney disease treatments that mimic the protective effects of genetic variants.

The firm closed an oversubscribed Series B financing round to fund a pivotal trial of RTx-015 and advance a clinical trial in ...

Regulators reviewed data from the Phase II FIREFLY-1 trial, in which the overall response rate was 53 percent, according to a scale for low-grade gliomas.

Researchers at AACR shared data on their model's ability to predict which NSCLC patients are likely to respond to ...